Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men~* Women on oral contraception (for women of childbearing age).~* 18 to 60 years.~* First admission to the episode of renal colic without evidence of complication (afebrile without renal input, negative beta-hCG (women of childbearing age) without severe vomiting without uropathy malformation known underlying balance sheet. ).~* In ability to deliver its consent.~* patient with a single calculation pelvic ureteral 4 to 10 mm cross-sectional diameter, with or without calyx calculations (not obstructive), but other calculation ureter.~* Unique pelvic stone :~* Proven by imaging: helical scan without contrast injection-ASP abdominopelvic.~* Radio-opaque to the ASP.~* More than 3mm and \<11mm (4 to 10 mm) of cross-sectional diameter.~Exclusion Criteria:~* Pregnant or lactating women scalable~* No oral contraception~* Contraception by intrauterine device .~* Concurrent infection ( positive urine test strip for Nitrites and / or general signs tanks (T ° C \> 38 ° 5 or \<36 ° 5 or chills) .~* Renal failure ( Creatinine clearance calculated by Cockcroft and Gault \<60 mL / min).~* Single functional kidney .~* Treatment with calcium channel blockers or alpha blockers.~* Recent or upcoming cataract surgery .~* Orthostatic hypotension .~* A history of peptic ulcer disease , liver disease , allergy to paracetamol , the ketoprofen .~* History of stroke , heart disease, diabetes.~* History of allergy to any treatment plans.~* Refusal to enter the protocol.~* Already included in the protocol.~* Medication against -indicated in combination with NSAI (vitamin K ..)~* Hepatic Impairment~* Participation in other biomedical research~* Patients with a history of hypersensitivity such as bronchospasm , asthma, rhinitis , urticaria~* Patients with asthma associated with chronic rhinitis, chronic sinusitis and / or nasal polyposis~* History of gastrointestinal bleeding or perforation during previous treatment with NSAI or history of gastrointestinal diseases such as ulcerative colitis, Crohn's diseases, gastrointestinal bleeding , cerebrovascular bleeding or other bleeding evolving~* Patients receiving treatment associated may increase the risk of ulceration or bleeding (glucocorticoids , selective serotonin reuptake inhibitors and antiplatelet agents such as aspirin )~* Patients with uncontrolled hypertension, congestive heart failure , ischemic heart disease, peripheral arterial disease, and / or a history of stroke (including transient ischemic attack)~* Patients treated with potassium-sparing drugs~Pelvic stone :~* Multiple~* Size \< 4 mm or \> 10mm~* Radiolucent~* Not formally identified by imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- standard treatment with Silodosin (Type: EXPERIMENTAL): Silodosin
- standard treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).